FI925727A0 - Transdermal dosering av burprenorfin - Google Patents

Transdermal dosering av burprenorfin

Info

Publication number
FI925727A0
FI925727A0 FI925727A FI925727A FI925727A0 FI 925727 A0 FI925727 A0 FI 925727A0 FI 925727 A FI925727 A FI 925727A FI 925727 A FI925727 A FI 925727A FI 925727 A0 FI925727 A0 FI 925727A0
Authority
FI
Finland
Prior art keywords
burprenorfin
dosering
transdermal
transdermal dosering
Prior art date
Application number
FI925727A
Other languages
English (en)
Other versions
FI925727A (fi
Inventor
Kuldeepak Sharma
Samir D Roy
Eric J Roos
Original Assignee
Cygnus Therapeutic Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygnus Therapeutic Systems filed Critical Cygnus Therapeutic Systems
Publication of FI925727A publication Critical patent/FI925727A/fi
Publication of FI925727A0 publication Critical patent/FI925727A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI925727A 1990-06-20 1992-12-16 Transdermal dosering av burprenorfin FI925727A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/540,908 US5069909A (en) 1990-06-20 1990-06-20 Transdermal administration of buprenorphine
PCT/US1991/004189 WO1991019474A1 (en) 1990-06-20 1991-06-12 Transdermal administration of buprenorphine

Publications (2)

Publication Number Publication Date
FI925727A FI925727A (fi) 1992-12-16
FI925727A0 true FI925727A0 (fi) 1992-12-16

Family

ID=24157413

Family Applications (1)

Application Number Title Priority Date Filing Date
FI925727A FI925727A0 (fi) 1990-06-20 1992-12-16 Transdermal dosering av burprenorfin

Country Status (10)

Country Link
US (1) US5069909A (fi)
EP (1) EP0535111A4 (fi)
JP (1) JPH06501243A (fi)
AU (1) AU646606B2 (fi)
CA (1) CA2085126A1 (fi)
FI (1) FI925727A0 (fi)
IE (1) IE912108A1 (fi)
NZ (1) NZ238587A (fi)
PT (1) PT98051A (fi)
WO (1) WO1991019474A1 (fi)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
SE9003665D0 (sv) * 1990-11-16 1990-11-16 Kabivitrum Ab Morphine prodrugs
WO1993014727A1 (en) * 1992-01-31 1993-08-05 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
JPH08503465A (ja) * 1992-11-09 1996-04-16 ファーメトリックス コーポレイション ケトロラックの経皮デリバリー
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
WO1994010987A1 (en) * 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5362566A (en) * 1993-03-04 1994-11-08 Minnesota Mining And Manufacturing Company Coating composition, granules coated with same, and method of reducing dust generation
AU6491494A (en) * 1993-04-07 1994-10-24 Rexham Industries Corp. Method of coating microporous membranes and resulting products
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5866143A (en) * 1995-03-24 1999-02-02 El Khoury And Stein, Ltd. Topical application of opioid drugs such as morphine for relief of itching and skin disease
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5667799A (en) * 1995-10-30 1997-09-16 Caldwell; Larry J. Method for treating headache pain with topical local anesthetic compositions
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
JPH1036265A (ja) 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
DE19746191C2 (de) 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
US6103771A (en) * 1998-03-20 2000-08-15 Caldwell Galer Incorporated Method of treating neuroma pain
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
KR100383252B1 (ko) * 1998-12-17 2003-07-16 주식회사 삼양사 부프레놀핀을함유하는경피투여조성물및이를포함하는패취
DE19901085C2 (de) * 1999-01-14 2003-12-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps
PL357158A1 (en) 2000-02-08 2004-07-12 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
RU2708563C2 (ru) * 2001-03-16 2019-12-10 Алза Корпорейшн Трансдермальный пластырь для введения фентанила
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1485051B1 (en) * 2002-03-20 2008-05-07 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
DE60312160T2 (de) 2002-06-10 2007-10-31 Euro-Celtique S.A. Entsorgungssysteme für transdermale abgabevorrichtungen zur verhinderung des missbrauchs von darin enthaltenen wirkstoffen
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
JP4642467B2 (ja) * 2002-08-20 2011-03-02 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
US7084150B2 (en) * 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
AU2003297074A1 (en) * 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
EP1572167B1 (en) * 2002-12-13 2008-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
EP1610791B1 (en) 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
KR20060054346A (ko) * 2003-07-25 2006-05-22 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20080233178A1 (en) 2004-02-23 2008-09-25 Euro-Celtique S.A. Abuse Resistant Opioid Transdermal Delivery Device Containing Opioid Antagonist Microspheres
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
ES2596809T3 (es) * 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
FR2879931B1 (fr) * 2004-12-24 2007-03-30 Rhodia Chimie Sa Materiau silicone pour la liberation d'une molecule active
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
NZ568313A (en) * 2005-11-21 2011-11-25 Schering Plough Ltd Pharmaceutical compositions comprising buprenorphine
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070248657A1 (en) * 2006-04-25 2007-10-25 Smith David J Multi-compartment transdermal pain control device
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
WO2008051889A1 (en) 2006-10-24 2008-05-02 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
RU2499583C2 (ru) * 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
JP2011526889A (ja) 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2366388A1 (de) 2010-03-17 2011-09-21 Ratiopharm GmbH Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
DK2557924T3 (da) 2010-04-13 2019-09-23 Relmada Therapeutics Inc Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2012085656A2 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
KR20140075807A (ko) 2010-12-23 2014-06-19 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
DE102011076653A1 (de) 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
HRP20211539T1 (hr) 2011-09-19 2021-12-24 Orexo Ab Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
KR102014565B1 (ko) 2011-12-12 2019-08-26 에르테에스 로만 테라피-시스테메 아게 부프레노르핀을 포함하는 경피 전달 시스템
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
JP6370802B2 (ja) 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
DK2810646T3 (en) 2013-06-04 2016-10-31 Lts Lohmann Therapie Systeme Ag A transdermal
PT3019167T (pt) 2013-07-12 2021-03-04 Knopp Biosciences Llc Tratamento de níveis elevados de eosinófilos e/ou basófilos
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
CA2978605A1 (en) 2015-03-02 2016-09-09 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP2018526415A (ja) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー 経皮送達システム
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
WO2018064544A1 (en) 2016-09-29 2018-04-05 Gesea Biosciences Inc. Bioerodible contraceptive implant and methods of use thereof
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2020124073A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3734097A (en) * 1969-04-01 1973-05-22 Alza Corp Therapeutic adhesive tape
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
DE3862405D1 (de) * 1987-03-09 1991-05-23 Alza Corp Zusammensetzung zur vorbeugung einer kontaktallergie durch gleichzeitiges verabreichen eines kortikosteroids mit einem sensiblisierenden arzneistoff.
JPH02503672A (ja) * 1987-06-01 1990-11-01 ワーナー‐ランバート・コンパニー 水性の系における浸透促進剤としての脂肪酸およびその短鎖エステル
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
DE3939376C1 (fi) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
CA2062828C (en) * 1990-04-24 1996-04-16 Osafumi Hidaka Pharmaceutical plasters

Also Published As

Publication number Publication date
EP0535111A1 (en) 1993-04-07
PT98051A (pt) 1992-04-30
WO1991019474A1 (en) 1991-12-26
EP0535111A4 (en) 1993-10-20
AU646606B2 (en) 1994-02-24
IE912108A1 (en) 1992-01-01
JPH06501243A (ja) 1994-02-10
CA2085126A1 (en) 1991-12-21
FI925727A (fi) 1992-12-16
AU8072291A (en) 1992-01-07
NZ238587A (en) 1994-06-27
US5069909A (en) 1991-12-03

Similar Documents

Publication Publication Date Title
FI925727A (fi) Transdermal dosering av burprenorfin
FI930886A0 (fi) Foerfarande foer hindrande av avstoetning av transplanterad vaevnad
FI932336A0 (fi) Inhibering av celladhesionprotein-kolhydratvaexelverkan
FI930848A (fi) Foerfarande foer separering av ilmenit
FI931357A (fi) Framstaellning av polyhydroxifettsyraamider i naervaro av loesningsmedel
FI930165A0 (fi) Framstaellning av synnerligen aktiva tvaettmedelspartiklar
FI931355A (fi) Fasoeverfoeringsmedierat foerfarande foer framstaellning av glukamidtvaettmedel
FI931356A (fi) Foerbaettrat katalytiskt foerfarande foer framstaellning av glukamidtvaettmedel
FI925805A (fi) Framstaellning av kompositmaterial
FI925609A0 (fi) Foerfarande foer framstaellning av sykliska sulfater
FI931879A (fi) Framstaellning av en peroxosyra
FI923779A (fi) Foerbaettringar i tillverkningen av nylongarn
FI931534A (fi) Foerfarande foer foerbaettring av aktiveringen av hydrauliskt masugns slagg foer framstaellning av byggnadsmaterial
FI930034A0 (fi) Foerfarande foer framstaellning av avlaongt foeremaol
FI925544A (fi) Bensoesyraderivat foer behandling av leukotrienassocierade sjukdomar
FI925546A (fi) Amidkopplade pyridylbensoesyraderivat foer behandling av leukotrien-associerade sjukdomar
FI930013A (fi) Hormonderivat av bakre hypofysloben
FI930123A (fi) Foerfarande foer anvaendning av oxiderade lipoproteiner i virusartade infektioner
FI923795A (fi) Kretselement foer aostadkommande av en spaerrspaenning foer kopplinsdioder
FI932198A0 (fi) Anordning foer skydd av kondensorroer
FI924154A (fi) Foerfarande foer framstaellning av penem-estrar
FI932901A0 (fi) Foerfarande foer framstaellning av alkalimonofluorfosfat
FI88315C (fi) Foerfarande foer blekning av cellulosamassa
FI931931A (fi) Foerfarande foer framstaellning av syntetisk wollastonit
FI932011A0 (fi) Anvaendning av klorsyrlighet foer avlaegsnande av svaveldioxid fraon roekgaser

Legal Events

Date Code Title Description
FD Application lapsed